	US 12,269,901 B2
	Peptide and use thereof
Hae Jin Kim, Daejeon (KR); Eun-Joung Moon, Daejeon (KR); and Young Hoon Lee, Sejong (KR)
Assigned to ENSOL BIOSCIENCES, INC., Daejeon (KR)
Appl. No. 17/434,464
Filed by ENSOL BIOSCIENCES, INC., Daejeon (KR)
PCT Filed Mar. 5, 2020, PCT No. PCT/KR2020/003132 § 371(c)(1), (2) Date Aug. 27, 2021, PCT Pub. No. WO2020/184901, PCT Pub. Date Sep. 17, 2020.
Claims priority of application No. 10-2019-0028654 (KR), filed on Mar. 13, 2019.
Prior Publication US 2022/0135621 A1, May 5, 2022
Int. Cl. A61K 38/00 (2006.01); A61P 1/18 (2006.01); C07K 7/06 (2006.01)

CPC C07K 7/06 (2013.01) [A61P 1/18 (2018.01); A61K 38/00 (2013.01)]

5 Claims

1. A method of treating or preventing insulitis, comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a peptide consisting of the amino acid sequence of SEQ ID NO:1 or the pharmaceutically acceptable salt thereof.